{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:33:48Z","timestamp":1786883628123,"version":"build-2736575974"},"reference-count":160,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.1080\/13543776.2022.2083501","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T12:38:56Z","timestamp":1654000736000},"page":"849-883","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":39,"title":["An updated patent review on monoamine oxidase (MAO) inhibitors"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5452-8869","authenticated-orcid":false,"given":"Paolo","family":"Guglielmi","sequence":"first","affiliation":[{"name":"Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-9440","authenticated-orcid":false,"given":"Simone","family":"Carradori","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-7326","authenticated-orcid":false,"given":"Ilaria","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5870-7509","authenticated-orcid":false,"given":"Cristina","family":"Campestre","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7114-8120","authenticated-orcid":false,"given":"Jacobus P.","family":"Petzer","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-7757-9_5"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.22.1.197"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-018-1927-8"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710626105"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1038\/nsb732"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043364784"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706464"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113190990406"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1883"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1709-8"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.11.1209"},{"issue":"3","key":"cit0012","first-page":"574","volume":"206","author":"Nelson SD","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"cit0013","first-page":"31","volume":"26","author":"Da Prada M","year":"1988","journal-title":"J Neural Transm Suppl"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11096su1c.03"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00245.x"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.5.6.811"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25032"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12part2.174S"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(97)00037-7"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.20.6385"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10191"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000343"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200011000-00005"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.02.024"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70073-4"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.01.007"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.511612"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1021\/jm070677y"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1021\/jm101359c"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008239"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.5607\/en.2013.22.1.1"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M206830200"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4886(03)00250-4"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1524876"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M500949200"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-003-0828-6"},{"issue":"4","key":"cit0037","first-page":"306","volume":"12","author":"Campi N","year":"1990","journal-title":"Clin Ther"},{"issue":"3","key":"cit0038","first-page":"234","volume":"24","author":"Filip V","year":"1999","journal-title":"J Psychiatry Neurosci"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2016.1260189"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.04.034"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241653"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.2c00001"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-813X(02)00109-2"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1007\/164_2020_384"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2013.12.032"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-018-1908-y"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70982"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.15.12.1763"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2010.495716"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.698613"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.982535"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2018.1427735"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2019.1637415"},{"key":"cit0055","unstructured":"University of Ljubljana. Disubtituted azetidines, pyrrolidines, piperidines and azepanes as inhibitors of monoamine oxidase b for the treatment of neurodegenerative diseases. WO2018055096A1.2018"},{"key":"cit0056","unstructured":"University of Ljubljana. (Z)-Vinyl substituted piperidines as inhibitors of monoamine oxidase A for the treatment of depression and other affective disorders. SI25271A. 2018."},{"key":"cit0057","unstructured":"Jiangxi University of Traditional Chinese Medicine. Propargylamine derivative and synthesis method thereof. CN111170877A. 2020"},{"key":"cit0058","unstructured":"Jiangxi University of Traditional Chinese Medicine. Application of propynylamine derivative in pharmacy. CN111228252A. 2020"},{"key":"cit0059","unstructured":"Guangdong Hec Pharmaceutical. Nitrogen-containing heterocyclic amide derivative and use thereof. CN108912029A. 2018"},{"key":"cit0060","unstructured":"Guangdong Hec Pharmaceutical. Alpha-aminoamide derivative and application thereof. CN109251155A.\u00b72019"},{"key":"cit0061","unstructured":"Sunshine Lake Pharma Co Ltd. Pyrrolidineamide derivatives and uses thereof. WO2019170115A1. 2019"},{"key":"cit0062","unstructured":"Guangdong Hec Pharmaceutical. Morpholine amide derivative and application thereof. CN112010818A.\u00b72020"},{"key":"cit0063","unstructured":"Korea Institute of Science and Technology. Novel heteroaryl amide derivatives as MAO-B inhibitors and pharmaceutical compositions for preventing ameliorating or treating neurodegenerative diseases comprising the same. KR20210033275A. 2021"},{"key":"cit0064","unstructured":"Beijing Jiachenhong Bio-Technology Co Ltd. Substituted phenoxyamide derivative, use thereof and drugs for treating Parkinson\u2019s disease. WO2021104507A1.\u00b72021."},{"key":"cit0065","unstructured":"China Pharmaceutical University. Donepezil-BHT heterozygotes and preparation method and application thereof in treatment of Alzheimer\u2019s disease. CN109134350A.\u00b72019"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112650"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1021\/jm1013709"},{"key":"cit0068","unstructured":"Nanyang Normal University. Amine alkoxy chalcone compound and preparation method and application thereof. CN110240549A.\u00b72019"},{"key":"cit0069","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University. Composition for preventing or treating neurodegenerative disease comprising ethyl acetohydroxamate incorporated chalcones as an active ingredient. KR20210136464A. 2021."},{"key":"cit0070","unstructured":"Shenzhen Second People\u2019s Hospital. Chalcone derivative and application thereof. CN112898276A. 2021."},{"key":"cit0071","unstructured":"Second People\u2019s Hospital S. 3-hydroxychalcone derivative and application thereof. CN112939952A. 2021."},{"key":"cit0072","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of neurological disorder comprising furanochalcone. KR20190131792A. 2019."},{"key":"cit0073","unstructured":"Zhejiang University of Technology. Inhibitor for monoamine oxidase A. CN110642766A.\u00b72020."},{"key":"cit0074","unstructured":"Taizhou University. 1,3,5-oxadiazine compound and preparation and application thereof. CN113264899A.2021"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1021\/jm501690r"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.08.067"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2019.1653864"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00510"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201500059"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300048"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116558"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.07.037"},{"key":"cit0083","unstructured":"Huazhong Agricultural University. 1,3,5-oxadiazine compound and preparation and application thereofN-(2-pyrimidinyl)-2-azido-3-((2,2,6,6-tetramethylpiperidinyl)oxy)indoline as well as preparation and application thereof. CN110563701A. 2019."},{"key":"cit0084","unstructured":"Zhejiang University of Technology. N-2-pyridyl-2,3-diazide indoline compound and preparation and application thereof. CN110511208B. 2019."},{"key":"cit0085","unstructured":"Zhejiang University of Technology. N-2-pyrimidyl-3-fluoroindole compound and preparation method and application thereof. CN112574180A. 2021."},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1021\/ol035991a"},{"key":"cit0087","unstructured":"Yantai Institute of Coastal Zone Research. Chinese Academy of Sciences. Organic compound based on gallocyanine and application thereof. CN107722057A. 2018."},{"key":"cit0088","unstructured":"Shenyang Pharmaceutical University. Monoamine oxidase A inhibitor indocyanine coupling compounds and preparation method and use thereof. CN108752319A. 2018."},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1039\/C9CC07009E"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25092257"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15396-5"},{"key":"cit0092","unstructured":"University B. A novel selective MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases. WO2021173102A1. 2021"},{"key":"cit0093","unstructured":"University B. A novel selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases. WO2021173103A1. 2021"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.06.070"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.08.113"},{"key":"cit0096","unstructured":"Huazhong Agricultural University. Application of isobenzazole-1,3-diketone compound to preparation of monoamine oxidase inhibitor. CN108295064A. 2018."},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.2174\/1386207320666170227155517"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.13919"},{"key":"cit0099","unstructured":"Zhejiang University of Technology. Coumarin heterozygous pyridone compounds having iron chelation and monoamine oxidase B inhibitory activity as well as preparation and application of compounds. CN110218207A. 2019."},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.03.025"},{"key":"cit0101","unstructured":"Fudan University. Isocoumarin type derivative, and preparation method and medicinal applications thereof. CN110872268A. 2020"},{"key":"cit0102","unstructured":"Guangdong Hec Pharmaceutical. Alpha-aminoamide derivative and application thereof. CN111072604A. 2020"},{"key":"cit0103","unstructured":"Kunming Institute of Botany. Chinese Academy of Sciences. Phenylidene phenyl peptide compounds and medicinal composition and application thereof. CN108752300A. 2018."},{"key":"cit0104","unstructured":"Henan Bifu Pharmaceutical Co Ltd. Xinone compound with anti-depression activity and screening method thereof. CN113135886A. 2021."},{"key":"cit0105","unstructured":"Korea Institute of Science and Technology. 2.6-diarylbenzo[d]oxaoles as MAO-B inhibitors and pharmaceutical composition comprising the same as an active ingredient. KR102276079. 2021."},{"key":"cit0106","unstructured":"Huazhong Agricultural University. Application of 1,3-benzoxazolethiol-2-one compounds in preparing monoamine oxidase inhibitor. CN108379260A. 2018."},{"key":"cit0107","unstructured":"Huazhong Agricultural University. Application of 5H-thiazolo [3,2-a] pyrimidine-5-ketone compound in preparation of monoamine oxidase inhibitor. CN111840296A. 2020."},{"key":"cit0108","unstructured":"Huazhong Agricultural University. Application of triazine compound in preparation of monoamine oxidase inhibitor. CN108295074A. 2018."},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-020-10143-w"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.04.021"},{"key":"cit0111","unstructured":"Huazhong Agricultural University. Applications of 1-tetralone compound in preparation of monoamine oxidase inhibitors. CN111904956A. 2020."},{"issue":"11","key":"cit0112","first-page":"942","volume":"82","author":"R\u00edos JL","year":"2016","journal-title":"Planta Med"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-013-9490-6"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.6b03529"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.5b06043"},{"key":"cit0116","unstructured":"Shenzen Institute of Geriatrics. Preparation method and application of demethylberberine. CN111116578A. 2020"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104807"},{"key":"cit0118","unstructured":"Zibo Qidingli Patent Information Consultation Co Ltd. Application of lathyranone A to preparation of monoamine oxidase (MAO) inhibitor. CN107865833A. 2018."},{"key":"cit0119","unstructured":"Zibo Qidingli Patent Information Consultation Co Ltd. Applications of apigenin in preparation of monoamine oxidase (MAO) inhibitors. CN107837262A. 2018."},{"key":"cit0120","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of neurological disorder comprising genkwanin. KR102204860B1. 2019"},{"key":"cit0121","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of neuropschyatric disorder or nerve disorder comprising acacetin or its derivatives. KR101981736B1. 2019"},{"key":"cit0122","unstructured":"Zibo Qidingli Patent Information Consultation Co Ltd. Applications of isovetixin in preparation of monoamine oxidase (MAO) inhibitors. CN107837287A. 2018."},{"key":"cit0123","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of depression or anxiety comprising decursin. KR101902837B1. 2018"},{"key":"cit0124","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of depression or anxiety comprising purpurin. KR101841604B1. 2018"},{"key":"cit0125","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of depression or anxiety comprising alternariol monomethyl ether. KR101854762B1. 2018"},{"key":"cit0126","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of depression or anxiety comprising hispidol. KR102090089B1. 2020."},{"key":"cit0127","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of neurological disorder comprising Piloquinone or derivatives thereof. KR101938738B1. 2019"},{"key":"cit0128","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University, Myongji University Industry and Academia Cooperation Foundation and National Institute for Korean Medicine Development. Composition for preventing or treating of depression or anxiety comprising osthenol. KR20210054304A. 2021."},{"key":"cit0129","unstructured":"Industry Academic Cooperation Foundation of Sunchon National University and Suncheon Research Center for Natural Medicines. Composition for preventing or treating of neuronal disorder comprising phlorotannins. KR102242342B1. 2021"},{"key":"cit0130","unstructured":"Roar Holding LLC. Improved method for isolation of MAO inhibitors from tequila or other distilled agave fermentation products. WO2018187628Al. 2018"},{"key":"cit0131","unstructured":"Roar Holding LLC. Method for isolation of MAO inhibitors from tequila or other distilled agave fermentation products. US20180296629Al. 2018"},{"key":"cit0132","unstructured":"Roar Holding LLC. Method to improve beverage quality. US2020165552A1. 2020"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.67.7_suppl_2.S24"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314601"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11101318"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24102005"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.676239"},{"key":"cit0138","unstructured":"Kyowa Hakko Kirin Co. Ltd. Methods of treating patients suffering from movement disorders. US2018221377A1. 2018."},{"key":"cit0139","unstructured":"Intrabio Ltd. Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. WO2018178670A1. 2018"},{"key":"cit0140","unstructured":"University Northwestern. Compositions and methods to reduce pharmaceutical-induced toxicity. US2018153839A1. 2018"},{"key":"cit0141","unstructured":"Joslin Diabetes Center Inc. Monoamine oxidase inhibitors as modifiers of beta cell vulnerability in type 1 diabetes. WO2021133777A1.2021"},{"key":"cit0142","unstructured":"Epiaxis Therapeutics PTY Ltd. Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist. CA3083373A1. 2019."},{"key":"cit0143","unstructured":"Istituto di Ricerca Pediatrica Citt\u00e0 della Speranza. New use of inhibitors of monoamine oxidase type B. WO2019244014A2. 2019"},{"key":"cit0144","unstructured":"Brigham & Women Hospital Inc. Inhibition of monoamine oxidase subtype A (MAOA) mitigates cardiovascular calcification. WO2020198613A1. 2020"},{"key":"cit0145","unstructured":"University of Southern California. Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer. US2018177786A1. 2018"},{"key":"cit0146","unstructured":"Toxie Europe Intelligens Kemiai Szenzorokat Kutato Fejleszto Korlatolt Felelossegu Tarsasag. Monoamine oxidase B inhibitors for use in the prevention or treatment of prostate carcinoma. WO2021024005A1. 2021"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1021\/jm031087c"},{"key":"cit0148","unstructured":"Magid A, Ken G. Compositions and methods for treatment of depression and other diseases. WO2020168337A1. 2020"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(95)49038-8"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1021\/jm0506266"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1021\/jm8011867"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.2174\/1386207323666200428091306"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2019.00143"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23774"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26196019"},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.04.003"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(83)90039-5"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70292-6"},{"issue":"12","key":"cit0160","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2174\/0929867327666200903115138","volume":"28","author":"Anwar F","year":"2021","journal-title":"Curr Med Chem"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2083501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T20:43:54Z","timestamp":1675716234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2083501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":160,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"alternative-id":["10.1080\/13543776.2022.2083501"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2083501","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}